CDK4 and cancer: Tumour cells with diminished endocrine signalling can bypass CDK4/6 inhibition through upregulation of the JNK pathway and showed that in cancer cells with high oestrogen signalling, potentiation of CDK4/6 activation can occur through ERBB4 and ERK upregulation and activation.